# Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V

Study · id `cardio:ct-nct03565913` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03565913](<https://clinicaltrials.gov/study/NCT03565913>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03565913

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 269 participants.

## Technical summary

Registry record NCT03565913. Randomized; quadruple masking; primary purpose treatment. Start 2017-01-22 (actual); primary completion 2026-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 269 participants (enrolled count; ClinicalTrials.gov record NCT03565913, source copy `cardio:ctgov-nct03565913-2026-06-03`, retrieved 2026-10-26)
- Started: 2017-01-22 (actual) (ClinicalTrials.gov record NCT03565913, source copy `cardio:ctgov-nct03565913-2026-06-03`, retrieved 2026-10-26)
- Primary completion: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT03565913, source copy `cardio:ctgov-nct03565913-2026-06-03`, retrieved 2026-10-26)
- Completion: 2026-12-18 (anticipated) (ClinicalTrials.gov record NCT03565913, source copy `cardio:ctgov-nct03565913-2026-06-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03565913, source copy `cardio:ctgov-nct03565913-2026-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03565913-2026-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V
- Condition: CKD Stage 5
- Intervention (Drug): EffCaMgCit
- Intervention (Other): CaAcS
- Lead sponsor: University of Texas Southwestern Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: University of Texas Southwestern Medical Center (`cardio:org-university-of-texas-southwestern-medical-center`)

## Provenance

Content hash: d9f094cf29e218a2bc276496f9fcf1927a89de93fb19fb85ec99e0264c318570
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
